Countdown! Statutes of limitations for claims against 30 stocks expire in under one year; the first list is now published—investors must act immediately to file claims.

Zhang Yun, partner at Jiangsu Zhenze Law Firm, and her legal team issue a solemn reminder to all investors: safeguarding rights and interests in the capital market brooks no delay. Currently, the team is handling securities claim cases involving as many as 30 stocks whose statutes of limitations will expire within one year. Under relevant laws, the statute of limitations for securities litigation is three years; once this period lapses, even eligible investors will not receive compensation from listed companies, and the law offers no protection to those who remain silent. Poly United (002037): Investors who purchased Poly United shares between April 28, 2020, and January 20, 2023, and sold or continued holding them after January 21, 2023, while suffering losses, are eligible to file claims. (Plaintiff investors won the first-instance trial; the statute of limitations expires on January 20, 2026.) Aolian Electronics (300585): Investors who purchased Aolian Electronics shares between December 9, 2022, and the market close on February 21, 2023, and sold or continued holding them after the market opened on February 22, 2023, while suffering losses, are eligible to file claims. (High probability of winning; the statute of limitations expires on February 21, 2026.) ST Botian (603603): Investors who purchased *ST Botian shares between April 28, 2018, and March 31, 2023, and sold or continued holding them after April 1, 2023, while suffering losses, are eligible to file claims. (The statute of limitations expires on March 31, 2026.) Guangji Pharmaceutical (000952): Investors who purchased Guangji Pharmaceutical shares between April 29, 2022, and April 19, 2023, and sold or continued holding them after April 20, 2023, while suffering losses, are eligible to file claims. (The statute of limitations expires on April 19, 2026.) *ST Weilai (600532): Investors who purchased Weilai Shares between October 29, 2022, and April 25, 2023, and sold or continued holding them after April 26, 2023, while suffering losses, are eligible to file claims. (Plaintiff investors won the first-instance trial; the statute of limitations expires on April 25, 2026.) ST Aokang (603001): Investors who purchased ST Aokang shares before April 25, 2023, and sold or continued holding them after April 26, 2023, while suffering losses, are eligible to file claims. (The statute of limitations expires on April 25, 2026.) *ST Xinfang (002087): Investors who purchased *ST Xinfang shares between April 20, 2017, and April 26, 2023, and sold or continued holding them after April 27, 2023, while suffering losses, are eligible to file claims. (The statute of limitations expires on April 26, 2026.)

From frozen accounts to class-action lawsuits: Under A-share’s ‘comprehensive’ investor protection system, what kind of ‘nuclear fusion’ are your wealth and equity undergoing?

When your securities account is frozen overnight; when a company’s dedicated fundraising account is seized en masse; when the halo of being a ‘specialized, sophisticated, novel, and cutting-edge’ enterprise shatters into pieces upon issuance of a single administrative penalty; when the controlling shareholder faces not only billion-yuan fines but also potential imprisonment—this is not a scene from a disaster movie, but rather the everyday reality of China’s A-share market in 2026. Just during this year’s May 15th Investor Protection Day, we witnessed regulatory ‘spectacles’ destined for the history books: Yunchuang Data (Beijing Stock Exchange) subjected to ‘triple punishment’ and forced delisting; Qingyue Technology (STAR Market), found guilty of IPO fraud, had its fundraising accounts locked down preemptively; Yuandao Communications (ChiNext) initiated delisting proceedings due to fraudulent issuance; and Dongfang Tong’s class-action lawsuit officially commenced... All these developments signal that the A-share market’s dual-track system—combining strict regulation with robust investor protection—has now achieved full closure. In the past, investors were mere ‘weeds,’ harvested season after season; today, they are bona fide ‘shareholders,’ legally empowered with the ‘imperial sword’ of class-action lawsuits and advance compensation. For entrepreneurs, the former ‘endgame’ of wealth creation upon listing has abruptly transformed into an ‘infinite liability test’ beginning precisely at listing. As a lawyer who has studied numerous disputes over listed-company control rights and thousands of shareholder controversies, I must tell you a harsh truth: amid this ‘comprehensive’ system’s nuclear fusion, no one stands outside the blast radius. If you fail to understand the rules, the rules will come to ‘harvest’ you. I. The Thunderous Wrath: From ‘Case-by-Case’ Measures to ‘Standard Practice’—China’s A-Share Investor Protection ‘Comprehensive System’ Is Now Fully Operational In the past, retail investors often joked, ‘I bought stocks and became a shareholder,’ expressing their helpless resignation after getting stuck in losing positions. Yet starting today, ‘becoming a shareholder’ is no longer a joke—it confers real, potent legal standing for rights protection. Let us examine several landmark events from the past two weeks, which collectively sketch out a complete ‘battle map’ of investor protection. (1) Ultimate Sanction: The Integrated ‘Delisting + Account Freeze + Fines + Criminal Referral’ Approach In the past, if a listed company engaged in fraud, the worst outcome was delisting—while controlling shareholders had likely already cashed out and fled, leaving behind an empty shell and devastated investors. Today, however, that logic has completely collapsed. Case 1: Qingyue Technology (688496.SH)—The Collapse of the ‘Specialized, Sophisticated, Novel, and Cutting-Edge’ Myth This firm, crowned a national ‘Specialized, Sophisticated, Novel, and Cutting-Edge Small Giant,’ went public on the STAR Market at the end of 2022, raising RMB 824 million. Yet, truth cannot be concealed forever. On May 8, 2026, the China Securities Regulatory Commission (CSRC) announced that its IPO prospectus and multiple financial reports contained material misrepresentations, constituting fraudulent issuance. Administrative Penalty: The company and related individuals were jointly fined nearly RMB 200 million; several persons were banned from the securities market. Criminal Accountability: Leads on criminal offenses were referred to public security authorities; the controlling shareholder faces criminal liability. Delisting Action: The Shanghai Stock Exchange immediately initiated delisting procedures. Asset Preservation: As early as February this year, the CSRC proactively froze three of the company’s securities accounts and seven bank accounts—including all dedicated fundraising accounts—totaling RMB 134 million in raised capital. Lawyer’s In-Depth Analysis: Qingyue Technology’s case serves as a textbook example of ‘multi-dimensional strike.’ Note the timing: accounts were frozen in February—well before the CSRC issued its Administrative Penalty Pre-Notification Letter.

Chemours Investors Reminded of December 2026 Deadline for Securities Class Action Regarding Opteon Products

Oct 12, 2026

Faruqi & Faruqi, LLP reminds Chemours investors of the December 7, 2026 deadline to seek lead plaintiff status in a lawsuit alleging misleading statements about Opteon product demand caused a significant stock price drop.

巴士的報

2026-10-09

Chemours Company Faces Securities Fraud Class Action Over Opteon Demand Claims

2026-10-11

Chemours Faces Securities Lawsuit Over Disclosures and Guidance

2026-10-11

Chemours Company Faces Class Action Lawsuit Alleging Investor Harm

2026-10-12

Class Action Lawsuit Filed Against Chemours for Misleading Investors on Product Demand and Financial Guidance.

2026-10-12

Class Action Lawsuit Filed Against Chemours Over Overstated Demand and Lowered 2026 Guidance